• Explore /
  • Poster
  • / First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with <em>HER2</em> amplification (<em>HER2</em>amp<em>+</em>), <em>RAS</em> wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.

First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with HER2 amplification (HER2amp+), RAS wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.

Abstract Poster

Authors

Eiji Oki

Eiji Oki

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Eiji Oki , Kei Muro , Jun Watanabe , Kohei Shitara , Kentaro Yamazaki , Hisatsugu Ohori , Manabu Shiozawa , Hirofumi Yasui , Takeo Sato , Takeshi Naito , Yoshito Komatsu , Takeshi Kato , Junpei Soeda , Kouji Yamamoto , Riu Yamashita , Kiwamu Akagi , Atsushi Ochiai , Hiroyuki Uetake , Katsuya Tsuchihara , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies

Sub Track

Targeted Therapies

Clinical Trial Registration Number

NCT02394834

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 53)

DOI

10.1200/GO.2023.9.Supplement_1.53

Abstract #

53

Poster Bd #

C10

Abstract Disclosures

Similar Posters

First Author: Kei Muro

First Author: Takayuki Yoshino

First Author: Tanios S. Bekaii-Saab

First Author: Tanios S. Bekaii-Saab